论文部分内容阅读
作者应用改良的 Terasaki 和 McClelland 微量细胞毒性测定方法,对粒系前身细胞(CFU-C)血清抑制素作筛选检查。中性粒细胞减少症42例,再障62例,共计104例。发现血清有 CFU-C 抑制素19例,其中补体依赖16例,补体不依赖3例。粒细胞减少症中22例为特发性获得性的,其中2例血清有抑制素,为补体不依赖性;1例全身性红斑狼疮(SLE)病人血清有抑制素,为补体依赖性,12例先天性,3例药物性及4例 Felty 氏综合征病人血清均无抑制素。再障中46例为特发性的,其中13例血清有抑制素,均为补体依赖性;5例肝炎后再障,其中1例血清有抑制素,为补体依赖性;1例 SLE 及1例传染性单核细胞增多症
The authors used a modified Terasaki and McClelland microcytotoxicity assay to screen for granulocyte precursor cells (CFU-C) serum inhibin. Neutropenia in 42 cases, aplastic anemia in 62 cases, a total of 104 cases. Found in 19 cases of serum CFU-C inhibitor, including 16 cases of complement-dependent, complement-independent in 3 cases. 22 cases of neutropenia idiopathic acquired, of which 2 cases of serum inhibin, complement independent; 1 case of systemic lupus erythematosus (SLE) serum inhibin, complement-dependent, 12 Cases of congenital, 3 cases of drug and 4 cases of Felty’s syndrome serum no statin. Aplastic anemia in 46 cases of idiopathic, of which 13 cases of serum inhibin, are complement-dependent; 5 cases of aplastic anemia, of which 1 cases of serum inhibin, complement-dependent; 1 case of SLE and 1 Infectious mononucleosis syndrome